Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Quantification of rare somatic single nucleotide variants by droplet digital PCR using SuperSelective primers

  • Pablo-Fontecha, Verónica|||0000-0001-9084-4597
  • Hernández-Illán, Eva
  • Reparaz, Andrea
  • Asensio, Elena
  • Morata, Jordi|||0000-0002-6146-4322
  • Tonda, Raúl
  • Lahoz, Sara|||0000-0002-4491-9911
  • Parra, Carolina
  • Lozano, Juan José
  • García-Heredia, Anabel
  • Martínez-Roca, Alejandro
  • Beltran i Agulló, Sergi|||0000-0002-2810-3445
  • Balaguer, Francesc|||0000-0002-0206-0539
  • Jover, Rodrigo
  • Castells, Antoni|||0000-0001-8431-2033
  • Trullàs, Ramon
  • Podlesniy, Petar
  • Camps, Jordi|||0000-0003-2929-4228
Somatic single-nucleotide variants (SNVs) occur every time a cell divides, appearing even in healthy tissues at low frequencies. These mutations may accumulate as neutral variants during aging, or eventually, promote the development of neoplasia. Here, we present the SP-ddPCR, a droplet digital PCR (ddPCR) based approach that utilizes customized SuperSelective primers aiming at quantifying the proportion of rare SNVs. For that purpose, we selected five potentially pathogenic variants identified by whole-exome sequencing (WES) occurring at low variant allele frequency (VAF) in at-risk colon healthy mucosa of patients diagnosed with colorectal cancer or advanced adenoma. Additionally, two APC SNVs detected in two cancer lesions were added to the study for WES-VAF validation. SuperSelective primers were designed to quantify SNVs at low VAFs both in silico and in clinical samples. In addition to the two APC SNVs in colonic lesions, SP-ddPCR confirmed the presence of three out of five selected SNVs in the normal colonic mucosa with allelic frequencies ≤ 5%. Moreover, SP-ddPCR showed the presence of two potentially pathogenic variants in the distal normal mucosa of patients with colorectal carcinoma. In summary, SP-ddPCR offers a rapid and feasible methodology to validate next-generation sequencing data and accurately quantify rare SNVs, thus providing a potential tool for diagnosis and stratification of at-risk patients based on their mutational profiling.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Tetraploidy-associated genetic heterogeneity confers chemo-radiotherapy resistance to colorectal cancer cells

  • Galofré, Claudia|||0000-0003-4415-4987
  • Gönül Geyik, Öykü
  • Asensio, Elena
  • Wangsa, Darawalee
  • Hirsch, Daniela|||0000-0001-8883-922X
  • Parra, Carolina
  • Saez, Jordi|||0000-0003-4888-9323
  • Mollà, Meritxell|||0000-0001-6215-2251
  • Yüce, Zeynep
  • Castells, Antoni|||0000-0001-8431-2033
  • Ried, Thomas|||0000-0002-0767-6009
  • Camps Polo, Jordi|||0000-0003-2929-4228
Tetraploidy, or whole-genome duplication, is a common phenomenon in cancer and preludes chromosome instability, which strongly correlates with disease progression, metastasis, and treatment failure. Therefore, it is reasonable to hypothesize that tetraploidization confers multidrug resistance. Nevertheless, the contribution of whole-genome duplication to chemo-radiotherapy resistance remains unclear. Here, using isogenic diploid and near-tetraploid clones from three colorectal cancer cell lines and one non-transformed human epithelial cell line, we show a consistent growth impairment but a divergent tumorigenic potential of near-tetraploid cells. Next, we assessed the effects of first-line chemotherapeutic drugs, other commonly used agents and ionizing radiation, and found that whole-genome duplication promoted increased chemotherapy resistance and also conferred protection against irradiation. When testing the activation of apoptosis, we observed that tetraploid cells were less prone to caspase 3 activation after treatment with first-line chemotherapeutic agents. Furthermore, we found that pre-treatment with ataxia telangiectasia and Rad3 related (ATR) inhibitors, which targets response to replication stress, significantly enhanced the sensitivity of tetraploid cells to first-line chemotherapeutic agents as well as to ionizing radiation. Our findings provide further insight into how tetraploidy results in greater levels of tolerance to chemo-radiotherapeutic agents and, moreover, we show that ATR inhibitors can sensitize near-tetraploid cells to commonly used chemo-radiotherapy regimens.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Centrosome reduction in newly-generated tetraploid cancer cells obtained by separase depletion

  • Galofré, Claudia|||0000-0003-4415-4987
  • Asensio, Elena
  • Ubach, Maria
  • Torres, Irianna M.
  • Quintanilla, Isabel
  • Castells, Antoni|||0000-0001-8431-2033
  • Camps Polo, Jordi|||0000-0003-2929-4228
Tetraploidy, a common feature in cancer, results in the presence of extra centrosomes, which has been associated with chromosome instability (CIN) and aneuploidy. Deregulation in the number of centrosomes triggers tumorigenesis. However, how supernumerary centrosomes evolve during the emergence of tetraploid cells remains yet to be elucidated. Here, generating tetraploid isogenic clones in colorectal cancer and in non-transformed cells, we show that near-tetraploid clones exhibit a significant increase in the number of centrosomes. Moreover, we find that centrosome area in near-tetraploids is twice as large as in near-diploids. To evaluate whether centrosome clustering was occurring, we next analysed the number of centrioles revealing centriole amplification. Notwithstanding, more than half of the near-tetraploids maintained in culture do not present centrosome aberrations. To test whether cells progressively lost centrioles after becoming near-tetraploid, we transiently transfected diploid cells with siRNA against ESPL1 /Separase, a protease responsible for triggering anaphase, to generate newly near-tetraploid cells. Finally, using this model, we assessed the number of centrioles at different time-points after tetraploidization finding that near-tetraploids rapidly lose centrosomes over time. Taken together, these data demonstrate that although most cells reduce supernumerary centrosomes after tetraploidization, a small fraction retains extra centrioles, potentially resulting in CIN.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

PCIG, a web-based application to explore immune-genomics interactions across cancer types

  • Pedrola Gómez, Anna|||0000-0002-0490-3851
  • Franch-Expósito, Sebastià|||0000-0002-4542-1701
  • Lahoz, Sara|||0000-0002-4491-9911
  • Esteban-Fabró, Roger
  • Dienstmann, Rodrigo|||0000-0001-5997-318X
  • Bassaganyas, Laia|||0000-0002-4575-0214
  • Camps Polo, Jordi|||0000-0003-2929-4228
Genomic alterations can modulate the tumor immunophenotype depending on their nature and tissue of origin. Although this immune-genomic interaction may shape disease progression and response to immunotherapy, the factors governing such dynamics and the influence of each tissue-specific context remain poorly understood. Here, we have developed the PanCancer ImmunoGenomics (PCIG) tool, a web-based resource that provides researchers with the opportunity to mine immunome-genome relationships across several cancer types using data from the Pan-Cancer Analysis of Whole-Genomes (PCAWG) study, which comprises.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Copy-number intratumor heterogeneity increases the risk of relapse in chemotherapy-naive stage colon cancer

  • Lahoz, Sara|||0000-0002-4491-9911
  • Archilla, Ivan|||0000-0002-2142-0608
  • Asensio, Elena
  • Hernández-Illán, Eva
  • Ferrer Menduiña, Queralt|||0000-0003-3177-4618
  • López-Prades, Sandra|||0000-0001-8208-2959
  • Nadeu, Ferran|||0000-0003-2910-9440
  • Rey Azpiri, Javier del|||0000-0001-7887-7871
  • Sanz-Pamplona, Rebeca
  • Lozano, Juan José
  • Castells, Antoni|||0000-0001-8431-2033
  • Cuatrecasas, Miriam|||0000-0003-3063-0110
  • Camps Polo, Jordi|||0000-0003-2929-4228
Optimal selection of high-risk patients with stage II colon cancer is crucial to ensure clinical benefit of adjuvant chemotherapy. Here, we investigated the prognostic value of genomic intratumor heterogeneity and aneuploidy for disease recurrence. We combined targeted sequencing, SNP arrays, fluorescence in situ hybridization, and immunohistochemistry on a retrospective cohort of 84 untreated stage II colon cancer patients. We assessed the clonality of copy-number alterations (CNAs) and mutations, CD8 + lymphocyte infiltration, and their association with time to recurrence. Prognostic factors were included in machine learning analysis to evaluate their ability to predict individual relapse risk. Tumors from recurrent patients displayed a greater proportion of CNAs compared with non-recurrent (mean 31.3% versus 23%, respectively; p = 0.014). Furthermore, patients with elevated tumor CNA load exhibited a higher risk of recurrence compared with those with low levels [ p = 0.038; hazard ratio (HR) 2.46], which was confirmed in an independent cohort (p = 0.004; HR 3.82). Candidate chromosome-specific aberrations frequently observed in recurrent cases included gain of the chromosome arm 13q (p = 0.02; HR 2.67) and loss of heterozygosity at 17q22-q24.3 (p = 0.05; HR 2.69). CNA load positively correlated with intratumor heterogeneity (R = 0.52; p < 0.0001). Consistently, incremental subclonal CNAs were associated with an elevated risk of relapse (p = 0.028; HR 2.20), which we did not observe for subclonal single-nucleotide variants and small insertions and deletions. The clinico-genomic model rated an area under the curve of 0.83, achieving a 10% incremental gain compared with clinicopathological markers (p = 0.047). In conclusion, tumor aneuploidy and copy-number intratumor heterogeneity were predictive of poor outcome and improved discriminative performance in early-stage colon cancer. © 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Mutational Status of SMAD4 and FBXW7 Affects Clinical Outcome in TP53 -Mutated Metastatic Colorectal Cancer

  • Lahoz, Sara|||0000-0002-4491-9911
  • Rodríguez, Adela|||0000-0002-4899-6607
  • Fernández Barat, Laia|||0000-0001-7528-9636
  • Gorría, Teresa
  • Moreno, Reinaldo
  • Esposito, Francis|||0000-0002-5028-9637
  • Oliveres, Helena|||0000-0003-1801-1181
  • Albiol, Santiago
  • Saurí Nadal, Tamara|||0000-0002-7479-5120
  • Pesantez, David|||0000-0003-0257-8538
  • Riu-Viladoms, G.|||0000-0002-8259-0811
  • Cuatrecasas, Miriam|||0000-0003-3063-0110
  • Jares, Pedro
  • Pedrosa, Leire|||0000-0002-1852-4975
  • Pineda, Estela|||0000-0003-2128-747X
  • Castells, Antoni|||0000-0001-8431-2033
  • Prat, Aleix|||0000-0003-2377-540X
  • Maurel, Joan|||0000-0002-9413-5592
  • Camps Polo, Jordi|||0000-0003-2929-4228
The mutational status of certain genes can be useful to advance therapeutic decision making and clinical management of cancer patients. In metastatic colorectal cancer, current clinicopathological factors employed in clinical practice have low or modest individual effect on survival, leading to a poor ability to discriminate patients at high risk. Here, we obtained data from metastatic colorectal cancer patients undergoing molecular testing by targeted gene sequencing, and we identified SMAD4 and FBXW7 mutated genes as negative prognostic markers in TP53 -driven tumors, which also improved the predictive performance to discriminate high-risk patients beyond clinical factors alone. This negative prognostic impact of co-occurring SMAD4 / TP53 and FBXW7 / TP53 mutations was confirmed in an independent validation analysis using publicly available data. Next-generation sequencing (NGS) provides a molecular rationale to inform prognostic stratification and to guide personalized treatment in cancer patients. Here, we determined the prognostic and predictive value of actionable mutated genes in metastatic colorectal cancer (mCRC). Among a total of 294 mCRC tumors examined by targeted NGS, 200 of them derived from patients treated with first-line chemotherapy plus/minus monoclonal antibodies were included in prognostic analyses. Discriminative performance was assessed by time-dependent estimates of the area under the curve (AUC). The most recurrently mutated genes were TP53 (64%), KRAS or NRAS (49%), PIK3CA (15%), SMAD4 (14%), BRAF (13%), and FBXW7 (9.5%). Mutations in FBXW7 correlated with worse OS rates (p = 0.036; HR, 2.24) independently of clinical factors. Concurrent mutations in TP53 and FBXW7 were associated with increased risk of death (p = 0.02; HR, 3.31) as well as double-mutated TP53 and SMAD4 (p = 0.03; HR, 2.91). Analysis of the MSK-IMPACT mCRC cohort (N = 1095 patients) confirmed the same prognostic trend for the previously identified mutated genes. Addition of the mutational status of these genes upon clinical factors resulted in a time-dependent AUC of 87%. Gene set enrichment analysis revealed specific molecular pathways associated with SMAD4 and FBXW7 mutations in TP53 -defficient tumors. Conclusively, SMAD4 and FBXW7 mutations in TP53 -altered tumors were predictive of a negative prognostic outcome in mCRC patients treated with first-line regimens.